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c-MycAdultmammalian cardiomyocytes have a very limited capacity to proliferate, and consequently the loss of cells after
cardiac stress promotes heart failure. Recent evidence suggests that administration of hydrogen peroxide (H2O2),
can regulate redox-dependent signalling pathway(s) to promote cardiomyocyte proliferation in vitro, but the poten-
tial relevance of such a pathway in vivo has not been tested. We have generated a transgenic (Tg) mouse model in
which the H2O2-generating enzyme, NADPH oxidase 4 (Nox4), is overexpressed within the postnatal
cardiomyocytes, and observed that the hearts of 1–3 week old Tg mice pups are larger in comparison to wild type
(Wt) littermate controls.We demonstrate that the cardiomyocytes of Tgmouse pups have increased cell cycling ca-
pacity in vivo as determined by incorporation of 5-bromo-2′-deoxyuridine. Further, microarray analyses of the tran-
scriptome of these Tg mouse hearts suggested that the expression of cyclin D2 is signiﬁcantly increased. We
investigated the molecular mechanisms which underlie this more proliferative phenotype in isolated neonatal rat
cardiomyocytes (NRCs) in vitro, and demonstrate that Nox4 overexpression mediates an H2O2-dependent
activation of the ERK1/2 signalling pathway, which in turn phosphorylates and activates the transcription factor
c-myc. This results in a signiﬁcant increase in cyclin D2 expression, which we show to be mediated, at least in
part, by cis-acting c-myc binding sites within the proximal cyclin D2 promoter. Overexpression of Nox4 in NRCs re-
sults in an increase in their proliferative capacity that is ablated by the silencing of cyclinD2.We further demonstrate
activation of the ERK1/2 signalling pathway, increased phosphorylation of c-myc and signiﬁcantly increased expres-
sion of cyclin D2 protein in the Nox4 Tg hearts. We suggest that this pathway acts to maintain the proliferative ca-
pacity of cardiomyocytes in Nox4 Tg pups in vivo and so delays their exit from the cell cycle after birth.
© 2014 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/3.0/).1. Introduction
Unlike many other organs, the adult mammalian heart has a very
limited capacity to regenerate after injury. Adult cardiomyocytes are es-
sentially post-mitotic and do not re-enter the cell cycle in sufﬁcient
numbers to achieve efﬁcient repair, for example after an ischemic insult
(reviewed in [1]). However the foetal mouse heart can restore homeo-
stasis after injury by increased proliferation of existing cardiomyocytes
[2], and this ability is transiently maintained in the postnatal mouse
heart [3]. By 7 days of age this regenerative capacity is lost, as the
cardiomyocytes terminally exit the cell cycle [1,4].
Understanding the mechanisms underlying the cell-cycle arrest in
postnatal cardiomyocytes is therefore of paramount importance to in-
form future therapeutic strategies to increase the regenerative potentialnoviralNox4;AdβGal, adenovi-
e; Tg, transgenic; NRC, neonatal
+44 207 848 5193.
.
. This is an open access article underof the injured adult heart. There is now much evidence to suggest that
the proliferation of many cell types is under the control of redox-
regulated signalling pathways (reviewed in [5]). In particular the
ERK1/2 signalling cascade, activated by intracellular-generated reactive
oxygen species (ROS) acts to promote proliferation in various cell types
[6–8]. An important molecular mechanism underlying this ERK1/2 acti-
vation is thought to be the ROS-dependent inactivation of protein tyro-
sine phosphatases (PTPs) (reviewed in [9]). However, very little is
known of the molecular pathways which transduce ERK1/2 activation
to cell proliferation. In cardiac cells, treatment of neonatal mouse
cardiomyocytes in vitro with a low level of the ROS hydrogen peroxide
(H2O2) was shown to stimulate proliferation by approximately 30%
[10]. Further, in a separate study of cardiomyocytes differentiated
from murine ES cells, cardiotrophin-induced proliferation was shown
to involve the redox activation of ERK1/2 [11]. Recently, ERK1/2 activa-
tion was also shown to be associated with increased cytokine-induced
proliferation of the cardiac cell line, HL-1 [12].
It is nowevident that the family of NADPHoxidase proteins (Noxs) is
an important enzymatic generator of intracellular ROS which modulatethe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
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have been identiﬁed in mammalian species (Nox1–5 and Duox1/2)
which show speciﬁcity of cellular distribution, intracellular location,
mechanisms of action and types of ROS produced [14]. Many studies
have demonstrated that NADPH oxidases are involved in the regulation
of cell proliferation via redox-mediated cell signalling pathways in vitro,
and the involvement of ERK1/2 has been shown in many cases
(reviewed in [15]). However, the signiﬁcance of these observations
with respect to cardiomyocytes has not, thus far, been tested in vivo.
Various Nox isoforms are widely expressed in all cardiovascular cells,
and we and others have demonstrated previously that Nox2 and Nox-
4 are co-expressed in cardiomyocytes [16–18]. Of particular interest is
the observation that the expression of endogenous Nox4 within the
heart declines sharply over the period of birth [16]. Furthermore, by
contrast to Nox2 which generates the superoxide anion (O2−), Nox4
has been shown to produce predominantly H2O2 [19,20] which is
the speciﬁc type of ROS demonstrated to enhance cardiomyocyte
proliferation [10]. Thus, potentially, a decreased level of intracellular
Nox4-generated ROS and consequent downstream signalling within
cardiomyocytes after birth may contribute to their decline in prolifera-
tive potential in vivo.
Many studies have aimed at determining important regulatorymole-
cules that control proliferation of the cardiomyocyte, and its exit from
the cell cycle (reviewed in [21]). The cardiac expression levels of many
of the known mammalian cell cycle regulators such as cyclins, cyclin-
dependent kinases (Cdks) and Cdk inhibitors have been determined
over the periods of embryonic, perinatal and adult development. As
might be expected, positive cell cycle regulators (such as the cyclins
and Cdks) become downregulated as the cardiomyocytes exit the cell
cycle, while negative regulators (such as the Cdk inhibitors) frequently
are upregulated in post-mitotic cardiac cells [21]. Of particular note are
the D-type cyclins (cyclins D1, D2 and D3), which are all highly
expressed in the embryonic heart and become progressively downregu-
lated in the neonatal and adult cardiomyocytes. Ablation of all three D-
type cyclins in embryonic mice leads to cardiac abnormalities and
death [22]. By contrast, cardiac-speciﬁc transgenic overexpression of cy-
clin D1, D2 or D3 has been shown, per se, to promote DNA synthesis
within adult cardiomyocytes [23], and recently cyclin D2 overexpression
was demonstrated to be sufﬁcient to enhance overt cardiomyocyte pro-
liferation in the postnatal heart [24].
We demonstrate here that cardiomyocyte-speciﬁc overexpression
of Nox4 in a Tg mouse model results in an increase in the proliferative
capacity of the cardiomyocytes in the postnatal heart, and that this corre-
lates with a signiﬁcant increase in cyclin D2 expression. We have there-
fore investigated in vitro the ROS-dependent molecular mechanisms
which underlie this increase in cardiomyocyte-cycling and identify an
ERK1/2-dependent pathway that results in cyclin D2 upregulation via
the activation of the protooncogene, c-myc. Thusmediators of this path-
way, linking intracellular ROS to increased cyclin D2 expression may be
promising therapeutic targets to help promote cardiomyocyte prolifera-
tion after cardiac injury.
2. Materials and methods
2.1. Genetically-modiﬁed mice and experimental animals
Cardiomyocyte-targeted Nox4-transgenic (Nox4 Tg) mice have
been described previously [16]. Neonatal Sprague–Dawley rats (born
within 24 h) were purchased from Harlan Laboratories UK.
2.2. Cell culture
Neonatal rat cardiomyocytes (NRCs) were isolated and cultured as
previously described [16]. Where indicated, NRCs were treated with ei-
ther 20 μMPD98059 (Sigma,MEK1 inhibitor) or DMSO (0.1%) as vehicle
control. For catalase treatments, 400 U/ml of PEG-conjugated catalase(Sigma) was added overnight. Nuclear extracts were prepared as previ-
ously described [25].
2.3. Bromodeoxyuridine labelling and ELISA
Bromodeoxyuridine (BrdU) was used to label cycling cells in vivo. Ex-
perimental mice were injected intraperitoneally with BrdU (167 mg/kg;
Sigma) and sacriﬁced after 16 h, when the heart tissue was isolated.
DNA samples were puriﬁed, and coated overnight in triplicate onto 96
well plates, previously treated with poly L-lysine (0.01% in PBS), at a
ﬁnal concentration of 100 μg/ml in 1× SSC (150 mM sodium chloride,
15 mM sodium citrate) after boiling (5 min). Wells were blocked with
3% BSA, 1.5% normal goat serum for 1 h and subsequently incubated
for 2 h with 1:100 dilution of BrdU antibody (Abcam). After washing
with PBS, antibody binding was assessed using the peroxidase-based
immunodetection kit (Vectastain Elite ABC kit, Vector Laboratories) and
the 1-step ABTS solution (Thermo Scientiﬁc). Absorbance was measured
at 405 nm.
2.4. Construction of mouse cyclin D2 luciferase reporter plasmid and lucif-
erase reporter assays
The cyclin D2 luciferase reporter plasmidwas constructed by inserting
a 1766 bp PCR-ampliﬁed fragment of the cyclin D2 promoter (−15 bp to
−1781bp relative to the start of translation) between theKpn1 andXho1
sites of pGL4.22[luc2CP/Puro] luciferase vector (Promega) by standard
techniques. The mouse cyclin D2 promoter fragment was generated
with the primer pair 5′- GGAATGGTACCCGCCCCAAACTCATACTCAC -3′
(incorporating a 5′ Kpn1 restriction site) and 5′- GGAATCTCGAGACTCG
GTCCCGACTGTAAATT -3′ (incorporating a 3′ Xho1 restriction site),
using Herculase (Stratagene) and mouse genomic DNA as template. The
ﬁdelity of the plasmid constructwas conﬁrmedby sequencing. Alignment
of the mouse and human cyclin D2 promoter sequences was performed
using ClustalW software [26]. Luciferase reporter assays were performed
as previously described [27].
2.5. Viral transductions and siRNA-mediated knockdown in NRCs
Full-length mouse cDNA of Nox4 was obtained as a kind gift from
Thomas Leto. Adenoviral expression vectors were generated for
Nox4 (AdNox4) and β-galactosidase (AdβGal) as described previ-
ously [27]. Cells were transduced with adenoviral constructs at a
multiplicity of infection (MOI) of 20 and incubated overnight prior
to use. For siRNA studies, siRNA targeted against rat cyclin D2, rat
c-myc or scrambled control (Ambion) was transfected into NRCs at
a concentration of 5 nM using Lipofectamine2000™ reagent accord-
ing to the manufacturer's protocol.
2.6. Western blotting
Cells or tissue samples were homogenised and proteins were sepa-
rated for immunoblot analysis as previously described [27]. Nuclear ex-
tracts were prepared using the NE-PER nuclear protein extraction kit
(Thermo-Fisher) as per the manufacturer's instructions. Primary anti-
bodies and the dilutions that were used were as follows: phospho-p44/
p42 MAPK (ERK1/2 Thr202/Tyr204), p44/p42 MAPK (total ERK1/2), cy-
clin D1, Cdc2, Cdc6 and Cdk4 (Cell Signaling Technology; all used at a di-
lution of 1:1000); and cyclin D2, cyclin A2 (Abcam, 1:1000), lamin A/C
(Santa Cruz, 1:2000), total c-myc (1:1000, cell signalling), phosphor-c-
myc (Thr58/Ser62) (1:1000, Millipore) α-tubulin (1:4000) and β-actin
(1:5000, Sigma).
2.7. Cardiomyocyte isolation and volume measurements
Excised hearts were ﬁxed in 4% PFA for 4 h, washed with PBS and
subsequently digested with collagenases B and D (Roche: 1.8 mg/ml
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cardiomyocytes became dissociated. Isolated cardiomyocytes were
washed and stored in PBS. Cardiomyocyte volumes were then assessed
in aMultisizer-3 Coulter Counter (Beckman). For assessment of BrdU in-
corporation, aliquots of cellswere spun onto poly-L-lysine-treated slides
(1000 rpm, 3 min), in a Shandon Cytospin 4. Immobilised cells were
permeabilised (0.5% triton, 15 min) and then treated with 50 units/ml
RQ1 DNAse1 (Promega) at room temperature for 45 min before immu-
nostaining. For assessments of cell volume based on physical cell mea-
surements, mouse ventricular myocytes were isolated by Langendorff
perfusion and enzymatic dispersion. Mice were anaesthetized by intra-
peritoneal injection of sodium pentobarbitone (60 mg/kg) and heparin
(100 IU). Hearts were excised, transferred to ice cold perfusion buffer
[(mM): NaCl, 140; KCl, 5; NaH2PO4, 2; CaCl2, 1.36; MgSO4, 1.2; glucose,
10; HEPES, 5; Taurine, 20; creatine, 10; pH 7.3–7.4]. After cannulation,
hearts were mounted on Langendorff apparatus and perfused with
pre-warmed, oxygenated perfusion buffer, before calcium depletion
using EGTA (100 mM) containing buffer for 5 min and ﬁnally perfused
with 0.5 mg/ml collagenase (type 2, activity 285 U/ml, Worthington
Biomedicals, Lakewood, NJ, USA) for 13 min. Ventricular tissue was re-
moved, dispersed, triturated gently and ﬁltered through a 200 μm
nylon mesh before graded calcium reintroduction. The cell suspension
was allowed to stabilize at room temperature for 30 min and then
ﬁxed in 4% PFA (ﬁnal) for 2 h at 4 °C. Myocytes were measured along
their long axis to determine cell lengths and along the cross section at
their midpoint to determine cell width. On average, approximately
100 cells were analysed per condition from three different preparations.
Cell volume was calculated as previously described [28].
2.8. Echocardiography
Mice were anaesthetised with 1.5% isoﬂurane and imaged using a
Vevo 2100 Imaging System with a 40-MHz linear probe (Visualsonics,
Canada). Systolic function, septal and posterior wall thickness and
left ventricular diameter were assessed using M-mode imaging in
both short and long axis views. The relative wall thickness (RWT) in di-
astole for each heart was calculated as follows: RWT = (septal wall
thickness + posterior wall thickness) / left ventricular diameter.
2.9. cDNA synthesis and Q-PCR
Total RNA extraction, cDNA syntheses and Q-PCR analyses were
performed as described previously [29]. Forward (F) and reverse
(R) primers used to detect rat and mouse transcripts were as follows
(all 5′-3′): rat β-actin; F: CCCGCGAGTACAACCTTCT, R: CGTCATCCATGGCG
AACT; rat cyclin D2; F: CACCGACAACTCTGTGAAGC, R: CCACTTCAGCTTAC
CCAACAC;mouse β-actin; F: CTGTCGAGTCGCGTCCACCC, R: ATGCCGGAGC
CGTTGTCGAC; mouse Nox4; F: CCGGACAGTCCTGGCTTATC, R: TGCTTTTA
TCCAACAATCTTCT; mouse cyclin D2; F: TCCCGTTGAGTGGGGCAAGGT, R:
ACCCGAGACCACAGAAACAGCCT;mouse cdc2; F: GATACGAGTGTACACACA
CGA, R: AACCGGAGTGGAGTAACGAG;mouse cdk4; F: TCAGTGGTGCCAGA
GATGG, R: GGAAGGCAGAGATTCGCTTA; mouse cyclin A2; F: CAGCATGA
GGGCCATCCTT, R: GCAGGGTCTCATTCTGTAGTTTA; mouse cyclin D1; F:
AGCCAGCTGCAGTGCTGTAC, R: CTGGTGGTGCCCGTTTTG; mouse cdc6; F:
GAAATTGTGGAGTCGGATGTCA, R: CGACTCGCTGGGTGATTTACA; rat c-myc
F: GAATTTTTGTCTATTTGGGGACA; R: GCATCGTCGTGACTGTCG.
2.10. Immunocytochemistry and histochemistry
Immunocytochemistry andhistochemistrywere performed on 6-μm
sections cut from parafﬁn-embedded Wt or Tg hearts (including those
isolated from mice that had been injected with BrdU as described
above) or 8 μm sections cut from cryopreserved Wt or Tg heart tissue.
All sections were ﬁxed in 3.3% paraformaldehyde, and permeabilised
with 0.1% triton X-100 in PBS. FITC-conjugated wheat germ agglutinin
(WGA) was used to outline cardiomyocytes as described previously[16]. For BrdU staining, sections were initially treated with 1 N HCl
(10 min on ice), 2 N HCl (10 min at room temperature, then 20 min at
37 °C) and washed twice with borate buffer to facilitate antigen
exposure to the antibody. Primary antibodies against laminin (Sigma),
Ki67 (Vector Laboratories), cardiac troponin T (Abcam) and BrdU
(Abcam) were used at dilutions of 1:250, 1:200, 1:500 and 1:100
respectively. For laminin staining, antibody binding was assessed
using the peroxidase-based Vectstain Elite ABC kit and diaminobenzi-
dine (ImmPACT DAB; both Vector Laboratories). All other antibody
bindings were visualised using Alexa 568-conjugated anti-mouse IgG
and 488-conjugated anti-rabbit IgG secondary antibodies (Invitrogen
Molecular Probes; 1:200 dilution). Rat neonatal cardiomyocytes were
cultured on cover slips, before ﬁxation, permeabilisation and staining
as above. Images were visualised using a Nikon Axioscope microscope
with Openlab software (Improvision), an Olympus inverted ﬂuores-
cence microscope with Velocity software (PERKinElmer), or a Leica
scanning confocalmicroscope (TCS-SP5). Red and green ﬂuorescent sig-
nals were detected using appropriate ﬁlter sets (excitation 568/emis-
sion 620 nm or 488/emission 505–530 nm respectively). Confocal
images were acquired as transcellular 0.4 μm sections in the Z plane
(15 scans/plane).
2.11. Cell proliferation assays
NRCs were seeded (1.5 × 104 cells/well) on a 96-well cell culture
plate that had been coated with a 1% gelatin solution. Cells were
transduced with an adenovirus vector encoding either Nox4 (AdNox4)
or β-galactosidase (AdβGal) as control at anMOI of 20. Cells were incu-
bated for 24 h and cell proliferation was assessed by colorimetric MTS
assay (CellTiter 96® AQueous One Solution Cell Proliferation Assay,
Promega) as per manufacturer's instructions. Manual cell counts were
performed using a haemocytometer. Cells were seeded at a density of
2.5 × 105 cells/well in a 6-well cell culture plate and transduced with
virus as outlined above. After incubation cells were harvested by treat-
ment with trypsin–EDTA until a single cell solution was obtained and
counted. 6 repeats of each condition were performed.
2.12. Flow cytometry and cell cycle analysis
NRC cells were treated as indicated. A single cell suspension of cells
was obtained by trypsinisation and the cells wereﬁxed in 70%methanol
overnight. Cells were stained with propidium iodide (50 μg/ml dis-
solved in PBS containing 5 U/ml RNase A) and were analysed using a
FACScalibur ﬂow cytometer (BD Biosciences) using appropriate doublet
discrimination. A minimum of 10,000 cells were analysed per sample.
Cell cycle data were generated using ModFit LT version 4.0.
2.13. Statistics
Data are expressed as mean ± SEM. Comparisons between sample
groups or measurements at different time points were made by un-
paired two-tailed Student's t-test. Heart/body weight ratios of 5 and
7 week-old Wt and Tg mice were additionally analysed by one-way
ANOVA with Bonferroni post-hoc test, as indicated.
3. Results
3.1. Forced postnatal expression of Nox4 in cardiomyocytes in vivo results
in overt cardiac enlargement in mouse pups
We have described previously a Nox4 cardiac-speciﬁc overexpress-
ing transgenic (Tg) mouse in which the expression of Nox4 is under
the control of the alpha myosin heavy chain (αMHC) promoter [16,
29]. Consistent with the endogenous developmental pattern of expres-
sion of αMHC, Nox4 mRNA and protein expression are strongly upreg-
ulated, speciﬁcally within the myocardium, from birth in this mouse
Fig. 1. Forced postnatal expression of Nox4 in cardiomyocytes in vivo results in overt cardiac hypertrophy. (A) Q-PCR analysis of Nox4 mRNA expression in Tg andWt littermate control
mouse hearts at embryonic day 18 and 2 days and 7 weeks post-birth. Expression levels are normalised to those of β-actin and as expressed as arbitrary units relative to endogenousNox4
expression within the embryo (A.U.). (B) Nox4 protein levels in 2 day postnatal Wt and Tg hearts. (C) Representative picture depicting the proportional increase in the size of hearts iso-
lated from 2 week old Wt and Tg mice. (D) Quantiﬁcation of heart/body weight ratios of Wt (n = 15) and Tg (n = 12) mice. (E) Echocardiographic measurements of interventricular
septum thickness, left ventricular posterior wall thickness and relative wall thickness in 3 week oldWt (n= 5) and Tg (n = 7) mice taken at the end of diastole. (F & G) Representative
transverse heart sections for cardiomyocyte area determination fromWt and Tgmice stainedwith eitherWGA (F) or an antibody against laminin (G).Mean data are shown in a histogram
beneath each stained section. Scale bar, 10 μm. (H) Comparison of isolated cardiomyocyte cell volumes from 2 week old Wt and Tg animals, assessed on a Coulter Counter. All data are
presented as mean ± S.E. *P b 0.05, **P b 0.01.
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fected (Supplementary data, Fig. S1A). We reported that under normal
physiological conditions, the hearts of the adult Nox4-overexpressing
mice are phenotypically similar to those of wild type (Wt) littermatecontrols both in size and cardiac function [16]. However, at two weeks
of age we found that the Nox4 Tg mouse hearts were overtly enlarged
and exhibited a signiﬁcant, approximately 30% increase in heart
weight/body weight ratio when compared to Wt littermate controls
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surements conﬁrmed that there were signiﬁcant increases in both the
left ventricular posterior wall thickness and the interventricular septal
wall thickness at diastole in 3 week-old Tg mouse hearts when com-
pared with littermate Wt controls (Fig. 1E). Further, the relative left
ventricular wall thickness (RWT)was increased in the Tgmouse hearts,
consistent with concentric rather than eccentric hypertrophic growth
(Fig. 1E). Despite this hypertrophy the contractile function, as deter-
mined by ejection fraction,waspreserved in these Tgmice (Supplemen-
tary data, Fig. S1B). To show that the increase in heart size was not
due to potential positional effects of transgene insertion, the heart
weight/body weight ratios were also determined in a second, distinct,
cardiac-speciﬁc Nox4 Tg mouse line. A signiﬁcant difference in heart
weight/body weight was similarly evident in this line (4.80 ± 0.18 vs.
5.60± 0.23; Supplementary data, Fig. S1C), conﬁrming that this pheno-
type is indeed a result of Nox4 overexpression.
We initially investigated whether the increase in heart size could be
explained by increased cardiomyocyte size (cellular hypertrophy).
Transverse sections ofWt andTg 2-week-oldmouse heartswere stained
to determine the average cross-sectional cardiomyocyte area of the two
groups. As shown in Figs. 1G and H, no increase in the cross-sectional
area of the cardiomyocytes was observed, as assayed by histological
staining with wheat germ agglutinin (WGA; Fig. 1F), or by immunolog-
ical stainingwith an antibody to laminin (Fig. 1G). Further,wemeasured
the cellular volume of cardiomyocytes isolated from the 2 groups, and
found a small but signiﬁcant decrease in the average size of the Tg
cardiomyocytes (Fig. 1H). Thus the increase in heart size in the Tg
mice could not be explained by an increase in cardiomyocyte size.
3.2. Nox4 Tg hearts demonstrate increased cardiomyocyte cell cycling
To assess whether increased cellular proliferation and cardiomyocyte
cell number account for the increased heart/body weight ratio in Tg
mouse hearts, the nucleotide analogue bromo-deoxyuridine (BrdU)
was injected into 2-week-old Tg and Wt littermate mice, 16 h before
theywere sacriﬁced. To obtain a quantitativemeasure of BrdU incorpora-
tion inWt and Tg hearts, an ELISA assay for BrdU incorporation was per-
formed and showed an approximate 38% increase in BrdU incorporation
in Tg hearts when compared to Wt controls (2.27 ± 0.22 A.U. vs. 3.13 ±
0.32 A.U.; Fig. 2A). Consistentwith this observation, sections fromWt and
Tg hearts co-stained with DAPI and an anti-BrdU antibody revealed that
the proportion of BrdU-positive, and therefore actively cycling cells was
markedly higher in Tg heart sections, compared to Wt controls
(Fig. 2B). A signiﬁcant proportion of these BrdU-positive nuclei has a
distinctive morphology characteristic of longitudinal sectioning through
cardiomyocyte nuclei (white arrows in Fig. 2C). To deﬁnitively demon-
strate increased cycling of cardiomyocytes in this mouse model,
cardiomyocytes were isolated from (BrdU-injected) 2 week old Wt and
Tg hearts and co-stained with antibodies to cardiac α-actinin T (red)
and BrDU (green) (Figs. 2D&E). The proportion of cycling cardiomyocyte
nuclei was found to be signiﬁcantly greater in the Tg group (7.00% ±
0.84%, vs. 1.87% ± 0.41%; P b 0.001). Similar results were obtained in
heart sections stainedwith the cell cyclemarker, Ki67 (see Supplementa-
ry data, Figs. S2A–C). Thus cardiomyocyte-speciﬁc overexpression of
Nox4 in vivo resulted in a cell-autonomous increase in cell-cycling activity
which would explain the increased heart size that we observed.
3.3. Nox4 Tg hearts display increased levels of expression of speciﬁc cell-
cycle regulating genes, and in particular cyclin D2
Cellular proliferation is tightly controlled by members of the cyclin
and cyclin-dependent kinase (Cdk) family of proteins (reviewed in [4]).
Upon analysis of a microarray study comparing the transcriptomes of 2-
week old Nox4 Tg and Wt hearts that we have previously performed
[29], we observed a striking transcriptional upregulation of cyclin D2 ex-
pression in the Tg hearts. This was the only cyclin or Cdk family memberto show such a signiﬁcant (greater than 2-fold) increase in this array. Cy-
clin D2 is known to be both necessary and sufﬁcient for cardiomyocyte
cell cycling in vivo. Thus cell cycle re-entry is completely blocked in the
myocardium of cyclin D2-deﬁcient hearts [30] while the forced expres-
sion of cyclin D2 alone has previously been demonstrated to be sufﬁcient
to increase the cell cycling capacity of cardiomyocytes both in vitro and
in vivo [24,31,32]. The expression of cyclin D2 protein is high in the em-
bryonic heart, but drops dramatically after birth to very low levels in
the normal postnatal heart by 2 weeks of age (Fig. 3A), concomitant
with cardiomyocyte cell cycle exit. Q-PCR conﬁrmed that cyclin D2
mRNA was signiﬁcantly increased in hearts from two week old Tg com-
pared to Wt animals (Fig. 3B), and cyclin D2 protein levels were also
shown by immunoblot to be signiﬁcantly increased in these Tg hearts
(Fig. 3C).
More modest increases in mRNA levels of the cell-cycle-regulating
proteins, cyclin A2, cdc2 and cdk4 were also in our microarray screen
[29]. To further characterise the molecular mechanisms underlying the
increased cardiomyocyte cell cycling in this mouse model we therefore
determined the mRNA and protein levels of these genes, in the 2 week
Wt and Tg mouse hearts. We additionally investigated the expression
levels of cell division cycle 6 (cdc6), which was not found to be in-
creased at the level of mRNA in our microarray, but which is known to
be absolutely required for entry into S phase [33]. In broad agreement
with ourmicroarray data, themRNA expression levels of cdc2 and cyclin
A2 were found to be increased in Tg, compared to Wt hearts (Fig. 3D),
while at the protein level, we also observed a signiﬁcant increase in
cdc2, but not cyclin A2 (Fig. 3E). In the case of cdc6, in agreement
with our microarray data, we found no difference in the mRNA levels
between Tg and Wt hearts but we did observe a striking increase in
cdc6 protein levels, suggesting a post-transcriptional level of regulation
(Figs. 3D & E). For cdk4, we did not demonstrate a signiﬁcant difference
in mRNA or protein expression between Tg and Wt mouse hearts
(Figs. 3D & E).
3.4. Nox4 acts as an enzymatic source of ROS to promote proliferation of
neonatal cardiomyocytes via an ERK1/2-dependent mechanism
In order to investigate the molecular mechanisms underlying the
increased cardiomyocyte-cycling seen in the Nox4 Tg hearts, we
overexpressed Nox4 in isolated neonatal rat cardiomyocytes (NRCs).
NRCs were transduced with an adenoviral vector containing either a
Nox4 (AdNox4) or β-galactosidase (AdβGal) transgene for 24 h and car-
diomyocyte proliferation was assessed both by an MTS-based cell prolif-
eration assay and by physical counting of cardiomyocyte cell number.
As shown in Fig. 4A, Nox4 transduction increased Nox4 protein expres-
sion and furthermore induced a signiﬁcant increase in cardiomyocyte
proliferation, as assessed by the MTS-based assay (100 ± 8.38% vs.
127.96± 7.31%; Fig. 4B), and conﬁrmed by cell counting (Fig. 4C). In ad-
dition, FACS analyses revealed that this enhancement of cell proliferation
correlatedwith a signiﬁcant decrease (approximately 5%) in the percent-
age of cells in the G0/G1 phase of the cell cycle and a corresponding in-
crease in the proportion of cells present in the G2/M phase of the cell
cycle upon Nox4 overexpression (Fig. 4D). The proportion of cell in S
phase remained unchanged between the two groups.
We have shown previously that Nox4 activates ERK1/2 in HEK293
cells [34]. ERK1/2 is known to be a critical regulator of the cell cycle
and to promote and/or associate with increased proliferation in various
cell types [35], including NRCs [12]. In NRCs, overexpression of Nox4
signiﬁcantly increased ERK1/2 phosphorylation. Inhibition of MEK1
(an upstreamactivator of ERK1/2) by the addition of PD98059, inhibited
both the basal level of ERK1/2 activation, and the increased phosphory-
lation seen upon Nox4 overexpression (Fig. 4E). In addition, the Nox4-
dependent activation of ERK1/2 was demonstrated to be ROS-
dependent, as it was ablated by the addition of PEG-catalase (Fig. 4F).
We assessed the effect of the inhibition of ERK1/2 activation upon
cardiomyocyte cell cycling, and found that the presence of PD98059
Fig. 2. Nox4 transgenic hearts demonstrated increased cardiomyocyte cell cycling. (A) ELISA assay of BrdU incorporation from hearts isolated from BrdU injected 2 week old Wt and Tg
pups. Pups were injected with BrdU and sacriﬁced after 16 h. (B) Representative immunoﬂuorescence staining of transverse sections of equivalent parafﬁn-embedded hearts from
BrDU-injected Wt and Tg mouse pups. BrdU-labelled, DNA-synthesising nuclei (green) and DAPI-stained nuclei (blue) are visible. Scale bar, 60 μm. (C) Magniﬁed section from Tg heart
section above (white box) depicting BrdU-labelled nuclei. Elongated nuclei consistent with cardiomyocyte morphology are indicated by white arrows. Scale bar, 25 μm.
(D) Cardiomyocytes isolated from equivalent BrDU-injected Wt and Tg hearts were co-stained with antibodies against BrdU (green) and cardiac troponin T (red) and the cell nuclei
stain DAPI (blue). Representative images are shown at low magniﬁcation (10×; scale bar, 110 μm) and at higher magniﬁcation (20×; scale bar, 54 mm). (D) Quantitation of percentage
of BrdU-stained cardiomyocyte nuclei/ﬁeld of view (n = 13 & 7 ﬁelds of view, each comprising approx. 200 cardiomyocyte nuclei). All data are presented as mean ± S.E. *P b 0.05.
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(Fig. 4G). In addition, the decrease in the proportion of cells in the G1/
G0 phase of the cell cycle and the increase in the proportion of cells in
G2/M, that were apparent upon Nox4 overexpression, were ablated by
ERK1/2 inhibition (Fig. 4H). Thus Nox4-derived ROS acts, at least in
part, via a MEK1-dependent mechanism to activate ERK1/2 and conse-
quently promote proliferation in neonatal cardiomyocytes. Additional-
ly, consistent with our in vitro observations, ERK1/2 phosphorylationwas signiﬁcantly increased in Tg hearts when compared withWt litter-
mate control hearts (Fig. 4I).
3.5. Nox4-induced proliferation is mediated by the upregulation of cyclin
D2
Consistent with our in vivo data, isolated NRCs transduced with
AdNox4 showed both an increase in cyclin D2 mRNA expression
Fig. 3.Nox4 overexpression induces the upregulation of cyclinD2 in vivo. (A) Expression levels of cyclinD2protein during development fromWtmice at embryonic day 14.5, birth (day 0),
and 7 days and 14 days postnatal. (B) Q-PCR analysis of the relative expression of endogenous cyclin D2mRNA in 2 week oldWt and Tg mouse hearts. Triplicate, independent Tg andWt
littermate controls were analysed, and relative expression was normalised to β-actin in all cases. (C) Protein expression levels of cyclin D2 inWt and Tg hearts at 2 weeks of age. The his-
togram depicts the mean of triplicate, independent samples normalised to β − actin and expressed in arbitrary units (A.U.). (D) Q-PCR analysis of the relative mRNA expression of the
indicated cell cycle-related proteins, normalised to β-actin from 2week oldWt and Tgmice (n= 3 in each case). (E) Representative immunoblots and quantitative histograms of protein
expression levels normalised toβ-actin of the indicated cell cycle-related proteins in 2week oldWt and Tgmice (n=3 in all cases). All data are presented asmean± S.E. *P b 0.05; ns: not
signiﬁcant.
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when compared with AdβGal-transduced controls. Inhibition of ERK1/
2 activation with PD98059 both decreased the basal level of expression
of cyclin D2, and ablated the increases in cyclin D2 mRNA and protein
levels upon Nox4 overexpression (Figs. 5C & D).
To test the functional signiﬁcance of this Nox4-dependent increase
in cyclin D2 expression upon cardiomyocyte proliferation, we silenced
its expression in NRCs by siRNA. siRNA-mediated silencing resulted in
an approximate 50% knockdown of cyclin D2 protein levels (Fig. 5E),
and this depletion of cyclin D2 was sufﬁcient to ablate the Nox4-
induced increase in NRC proliferation (Fig. 5F). Therefore, the increase
in cyclin D2 expression is a necessary mediator of the increase in NRC
proliferation mediated by Nox4.3.6. Nox4 activates cyclin D2 expression via ERK-dependent phosphoryla-
tion of c-myc
It is known that a key positive regulator of cyclin D2 transcription is
c-myc [36,37] and that c-myc can be activated by phosphorylation of
Thr58 and Ser 62 by ERK1/2 [38,39]. We determined the levels of both
total and phospho-c-myc protein within the (2 week-old) Wt and
Nox4 Tg hearts and found that ratio of phospho-c-myc: total c-myc
was signiﬁcantly increased in the Tg mouse hearts (Fig. 6A). IsolatedNRCs transduced with AdNox4 in vitro similarly demonstrated a large
increase in phospho-c-myc compared to AdβGal-transduced controls,
and this increase was found to be ablated by ERK1/2 inhibition with
PD98059 (Fig. 6B). Thus Nox4 overexpression increases c-myc phos-
phorylation and activation via ERK1/2 in cardiomyocytes.
To determine whether c-myc is acting to increase cyclin D2 expres-
sion in the NRCs, we silenced c-myc by siRNA (Figs. 6C & D) and this
depletion of c-myc resulted in a signiﬁcant decrease in cyclin D2 expres-
sion that was apparent uponNox4 overexpression (Figs. 6E and F). Thus
consistent with previous reports [36,37], we found c-myc to be a posi-
tive regulator of cyclin D2 transcription, and additionally to be (at
least in part) responsible for mediating the Nox4-dependent increase
in cyclin D2 expression.3.7. Nox4-generated ROS increases the rate of cyclin D2 transcription via a
highly conserved, cis-acting promoter region containing functional c-myc
binding sites
To conﬁrm the role of c-myc in the transcriptional regulation of cy-
clin D2, we investigated its functional effect on the proximal cyclin D2
promoter.We cloned amouse genomic fragment, comprising this prox-
imal promoter region (−15 bp to−1781 bp relative to the translational
start site) upstream of a luciferase reporter gene (cyclin D2-luc). This
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mouse, suggesting functional signiﬁcance, and also includes a conserved
binding site for c-myc which has been shown previously to function in
the positive regulation of cyclin D2 transcription in murine ﬁbroblasts
[36,37] (Fig. 7A). Upon transfection into neonatal rat cardiomyocytes,
this fragment was sufﬁcient to direct a high level of transcriptional
activation, conﬁrming its promoter activity, and this activity wasFig. 4.Nox4 expression increased NRC proliferation via an ERK1/2-dependent pathway. NRCsw
30 h. (A) Immunoblot of Nox4 expression in transduced NRC cells. (B) MTS-based assessment o
cell count assessment of NRC proliferation after transduction with either AdNox4 or AdβGal (n
AdNox4 transduction (n = 3). (E & F) Representative immunoblots of phosphorylated and tota
sence of 20 μMPD98059 (E) or after catalase treatment (400U/ml overnight; F). Histograms rep
3). (G)MTS-based cell proliferation assay of NRCs after AdβGal or AdNox4 transduction in the p
or AdNox4 transduction in the absence (vehicle) or presence of 20 μMPD98059 (n=3). (I) Rep
ylation in 2 week-oldNox4 Tg hearts compared toWt controls (n= 3). The histogram represen
as mean ± S.E. *P b 0.05.signiﬁcantly increased, upon Nox4 overexpression. By contrast, Nox4
overexpression had no effect on the luciferase reporter activity resulting
from a promoterless luciferase vector, pGL4.22 (Fig. 7B). Further, the in-
crease in the cyclin D2 promoter activity upon Nox4 overexpression
was signiﬁcantly reduced in the presence of either c-myc siRNA or the
inhibitor of ERK1/2 (Figs. 7C & D). Therefore within NRCs, Nox4-
generated ROS stimulate ERK1/2 activation which results in increasedere transducedwith either Nox4 (AdNox4) orβ-galactosidase (Ad βGal) and incubated for
f NRC proliferation after transduction with either AdNox4 or AdβGal (n= 3). (C) Physical
= 3). (D) Cell cycle analysis of the G0/G1, S and G2/M populations of NRCs after AdβGal or
l ERK1/2 levels in NRCs after transduction with AdβGal or AdNox4 in the presence or ab-
resent the ratio of phosphorylated ERK1/2 to total ERK1/2 protein levels in each case (n=
resence or absence of 20 μMPD98059 (n=3). (H) Cell cycle analysis of NRCs after AdβGal
resentative immunoblot and quantitative histogram showing increased ERK1/2 phosphor-
ts the ratio of phosphorylated ERK1/2 to total ERK1/2 protein levels. All data are presented
Fig. 4 (continued).
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promoter via a cis-acting promoter element(s) to increase the rate of cy-
clin D2 transcription.
3.8. Overexpression of Nox4 in the postnatal heart prolongs the period of
cardiomyocyte cell cycling
As mentioned above, the increased heart weight/body weight ratios
of the Nox4 Tg hearts is transient. Thus we continue to observe signiﬁ-
cant differences in heart size at three and ﬁve week time points, but
this phenotype is lost by seven weeks of age (Fig. 8A). We assessed
the cell cycling status of the cardiomyocytes in the hearts of these
mice, after 7 weeks of age. Immunological staining for themitoticmark-
er Ki67, together with the cardiomyocyte-speciﬁc troponin I sarcomeric
protein, demonstrated that the Tg cardiomyocytes were no longer cy-
cling at 7 weeks post-parturition (Fig. 8B). Thus at this time point
Ki67 immunoreactivity was only apparent in non-cardiomyocyte cells.
Further, BrdU incorporation into the cardiomyocyte nuclei was no lon-
ger apparent in cells isolated from either the Wt or Nox4 Tg mouse
hearts (see Supplementary data, Fig. S3).
The transgenic expression of Nox4 (driven by the αMHC promot-
er) however remains at least as high in the adult (7 week) Tg mice as
in the 2-week-old mice (Fig. 1A & [29]). Further, the (ROS-depen-
dent) activation of ERK1/2 is sustained in the hearts of these adult
Tg mice, compared to Wt littermate controls (Fig. 8C). In addition,
cyclin D2 mRNA also remains overexpressed in the Tg adult mouse
hearts, and this increase in transcription is reﬂected in a signiﬁcant
increase in cyclin D2 protein at this stage (Figs. 8D & E). By contrast
however the protein levels of cdc2 and cdc6, which were elevated
in the 2 week old hearts, are no longer increased in the adult Tg
mouse hearts (see Supplementary data, Fig. S4). It has been shown
that the nuclear trafﬁcking of the D cyclins, including cyclin D2, is
an important regulator of the cell cycle (reviewed in [40]). We there-
fore assessed the sub-cellular localisation of cyclin D2 in the Wt andTg hearts at 2 days, 11 days and 7 weeks after birth. These data clear-
ly show signiﬁcant nuclear localisation of cyclin D2 in Wt and Tg
mouse hearts that is lost in the Wt mice by 11 days, concomitant
with the normal loss in cardiomyocyte cell cycling activity. By con-
trast, in the Tg mouse hearts, there remain signiﬁcant levels of cyclin
D2 at 11 days after birth (Figs. 8G, H). However no nuclear cyclin D2
is apparent in either Wt or Tg mouse hearts by 7 weeks of age
(Fig. 8I). Therefore a loss in nuclear cyclin D2 localisation correlates
with a loss in proliferative capacity in both Wt and Tg mouse hearts.
The loss of proliferative capacity of the cardiomyocytes in the adult
Tg hearts however does not fully account for the normalisation of the
heart sizes to those of the Wt animals. We therefore measured the di-
mensions of the cardiomyocytes isolated from these adult (male)
mice. Adult cardiomyocytes from both theWt and Tg cohorts were het-
erogeneous in size, and although there was a trend towards a smaller
cell size in the Tg group, this was not signiﬁcant (Fig. 8F). Similarly,
the cell volumes of isolated adult cardiomyocytes assessed in a Coulter
Counter were not found to be signiﬁcantly different between the two
groups (Supplementary data, Fig. S5). Although the accumulation of
cardiomyocytes in the G2/M cell cycle phase, upon ectopic expression
of Nox4 is likely a result of increased progression through the G1/S cell
cycle phase (see Section 4, Discussion), it can also be an indicator of cel-
lular senescence and/or apoptosis (reviewed in [41]). We therefore
assessed the degree of senescence and apoptosis within young (8 day-
old) and older (7 week-old) mice. No evidence of senescent cells was
apparent inWt or Tgmouse hearts at either time point (Supplementary
data, Fig. S7), and only minimal levels of apoptosis were apparent in all
cases (Supplementary data, Fig. S8). Thus, it appears that overexpres-
sion of Nox4 in the Tg cardiomyocytes prolongs the period of cardio-
myocyte cell cycling and proliferation in the ﬁrst 1–2 weeks after
birth. This is not sustained into adulthood, and the loss of proliferative
capacity correlates with a loss of nuclear-localisation of cyclin D2. The
mechanistic cause of the normalisation of the heart sizes in the older
Wt and Tg mice, however, remains to be elucidated.
Fig. 5.Nox4-induced proliferation in NRCs ismediated by the transcriptional upregulation of cyclin D2. (A) Q-PCR analyses showing relative cyclin D2mRNA expression, normalised to β-
actin (n = 3) and (B) representative immunoblots and quantitative histograms of protein expression levels normalised to those of laminin A/C in NRCs transduced with either Nox4
(AdNox4) orβ-galactosidase (AdβGal) as control, for 30 h (n=3). (C) Q-PCR analyses of cyclinD2mRNA levels inNRCs transducedwith either AdNox4 or AdβGal for 30 h in the presence
or absence of theMEK inhibitor, PD98059 (n= 3). (D) Representative immunoblot and quantitative histograms of cyclin D2 levels (relative to those of β-actin) in protein extracted from
cells as described in (C) (n=3). (E) Representative immunoblot and quantitative histogramof cyclinD2protein inNRCs after either scrambled (siScr) or cyclinD2 (siD2) siRNA treatment
(n= 3). (F)MTS-based cell proliferation assay of NRCs transducedwith either AdNox4 or AdβGal for 30 h in the presence of scrambled, or cyclin D2 siRNA (n= 3). All data are presented
as mean ± S.E. *P b 0.05.
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4.1. The cardiomyocyte cell cycle is under redox control in vivo
Understanding themolecular mechanisms which underlie the regu-
lation of the cardiomyocyte cell cycle is crucial in further developing
strategies to regenerate and repair cardiac tissue after ischemic or he-
modynamic insult. Mammalian cardiomyocytes exit from the cell
cycle shortly after birth. The data presented here demonstrate that the
cardiomyocyte cell cycle is, in part, under redox regulation in vivo. Pre-
vious studies had demonstrated that exogenous administration of H2O2
to mouse neonatal cardiomyocytes promoted proliferation in vitro [10],
andwe showhere that cardiac-speciﬁc overexpression of an enzymatic,
endogenous source of H2O2 (Nox4), can act crucially in vivo, to promote
cardiomyocyte cell cycling in the postnatal heart. Thus the Nox4 Tg
mouse pup hearts were larger than Wt litter mate controls, while the
volumes of the individual cardiomyocytes were slightly, but signiﬁcant-
ly, smaller, and displayed higher rates of DNA synthesis. A striking fea-
ture of the transcriptome of the Nox4 Tg mouse heart is a verysigniﬁcant increase in cyclin D2 mRNA. We propose that this increase
in cyclin D2 expression is critical to the increased cardiomyocyte cycling
seen in these Tg pups, and underlies their overt cardiac hyperplasia.
Thus cardiac-speciﬁc ectopic expression of cyclin D2 per se in transgenic
mice has previously been demonstrated to be sufﬁcient to increase
heart size and prolong cardiomyocyte cell cycling activity, as judged
by sustained DNA synthesis in cardiomyocytes in the adult heart [33].
Crucially, ectopic cardiac-speciﬁc expression of cyclin D2 has also been
shown to result in enhanced cardiac growth in the postnatal period
due to increased cardiomyocyte proliferation [24], as we suggest in
our Nox4 Tg model. Further, overexpression of cyclin D2 in NRCs
in vitro has similarly been shown to be sufﬁcient to increase DNA syn-
thesis and cell cycling [31], and we demonstrate here that inhibition
of cyclin D2 expression by siRNAwas sufﬁcient in NRCs to ablate the in-
crease in cell proliferation apparent upon Nox4 transduction.
Previous reports however have argued about the relative impor-
tance of either cyclin D1 or cyclin D2 in driving the progression of the
cardiomyocyte cell cycle [42]. As has been shown for cyclin D2, cyclin
D1 is also known to increase cardiomyocyte cell cycling activity
Fig. 6.Nox4 overexpression activates c-myc resulting in increased cyclinD2 expression. (A) Representative immunoblot showing increased c-myc phosphorylation in 2 week-oldNox4 Tg
hearts comparedwithWt littermate controls. The histogram represents the ratio of phosphorylated c-myc to total c-myc protein levels (n=3). (B) Representative immunoblot and quan-
titative histogram showing phosphorylated and total c-myc levels in NRCs transduced with either AdNox4 or AdβGal for 30 h in the presence or absence of PD98059 as indicated (n= 3).
(C) Q-PCR analyses of c-myc mRNA expression, relative to that of β-actin (n = 3), and (D) representative immunoblot indicating c-myc protein expression, in NRCs after 48 h of c-myc
siRNA treatment as indicated. β-Actin is shown as a loading control for protein expression. (E) Representative immunoblot and quantitative histogram showing cyclin D2 protein expres-
sion, relative to that of β-actin, in NRCs transduced with either AdNox4 or AdβGal for 30 h in the presence of scrambled or c-myc siRNA as indicated (n = 3). All data are presented as
mean ± S.E. *P b 0.05.
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D2 overexpression clearly demonstrate that both induce increased
cardiomyocyte cycling activity in vivo [23,33]. Cyclin D1 has also previ-
ously been suggested to be regulated by H2O2, via redox-dependent
stabilisation of the cyclin D1 protein [44]. However, we found no evi-
dence of increased cyclin D1 expression, at the level of either mRNA or
protein, in the hearts of the 2 week old Nox4 Tg mice, suggesting that
cyclin D1 is not the mediator of the increased cardiomyocyte prolifera-
tion in this mouse model (Supplementary data, Fig. S6).
We therefore aimed to elucidate in vitro the redox-dependentmech-
anisms underlying the positive regulation of cyclin D2 transcription and
cell proliferation seen upon Nox4 overexpression in NRCs. We show
here a (Nox4-generated) ROS-dependent activation of the ERK1/2
signalling pathway that mediates increased phosphorylation and
activation of c-myc, upregulation of cyclin D2 (mRNA and protein) ex-
pression and enhanced cardiomyocyte proliferation in vitro. This is con-
sistent with previous reports which have demonstrated activation of
the ERK1/2 signalling pathway by Nox4 in other cell types both
in vitro [34,45] and in vivo [46], while ERK1/2 activation is associated
with increased cellular proliferation in various other cellular settings
(reviewed in [47]). Further, we present evidence that the Nox4-
dependent increase in cyclin D2 expressionwas dependent upon the di-
rect activation of its transcription via the binding of c-myc to knownconserved binding site(s) within its proximal promoter region [37,48].
However, this does not exclude the potential involvement of other
redox-regulated transcription factors in the activation of cyclin D2 ex-
pression byNox4. Thus Sp1 and Stat5 are also knownpositive regulators
of the cyclin D2 promoter (Fig. 7A) [48], that are potentially regulated
by ROS via ERK1/2 activation [49,50] and may additionally contribute
to the full upregulation observed.
There have been several, sometimes conﬂicting, reports of the role of
Nox4 in cellular proliferation in diverse cell types. Thus ablation of Nox 4
in melanoma cells has been shown to inhibit proliferation, via regula-
tion of G2-M cell cycle progression [51], while in airway smooth muscle
cells Nox4was shown to be a positivemediator of TGF-β1-induced pro-
liferation. In the latter case the Nox4 was shown to inﬂuence cell cycle
transition through both G1/S and G2/M [52]. By contrast, in hepatocytes
ablation of Nox4 resulted in increased cell proliferation and resulted in a
higher proportion of cells in S and G2/M phases [53]. The differences in
these observations likely reﬂect both differences in subcellular
localisation of Nox4 and/or intracellular composition of targets of ROS
and associated signalling components between the different cell types.
We demonstrate here, that in cardiomyocytes Nox4-generated ROS is
a positive mediator of cell cycling, and that the increased proliferation
is associated with a lower proportion of cells in G0/G1, and a concomi-
tant increase in cell in the G2/M cell cycle phase. These results are
Fig. 7.Nox4-generated ROS increases the rate of cyclin D2 transcription via a highly conserved, cis-acting promoter fragment. (A) A DNA sequence comparison showing high conservation
between regions of the proximal human and mouse cyclin D2 promoter regions, upstream of exon 1. Functional binding sites for indicated transcription factors [37,48] are indicated and
shaded in grey. Stars indicate nucleotide homology between species. Nucleotides are numbered relative to start of translation of each gene. (B) Relative luciferase activity (RLA) resulting
from a promoterless ﬁreﬂy luciferase vector (empty vector) or from a construct comprising a 1766 bp genomic fragment of the proximalmouse cyclinD2promoter ligated upstreamof the
luciferase reporter gene (cyclin D2-luc) inNRCs transducedwith either AdNox4 or AdβGal for 28 h. (C &D)RLA resulting from the cyclin D2-luc inNRCs transducedwith either AdNox4 or
AdβGal for 28 h in the presence of scrambled or cmyc siRNA(C), or PD90859 (D), as indicated. In each case, luciferase activities are normalised to that of a co-transfected Renilla luciferase
vector and expressed as relative luminescence units (RLUs; n = 3). The RLU resulting from cyclin D2-luc transduced with AdβGal was set to 1.0 in each case. All data are presented as
mean ± S.E. *P b 0.05.
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pression, seen upon Nox4 overexpression, is acting to promote the G1/S
phase transition in the cardiomyocytes, as has been reported previously
in other cell types [54].
The in vitro observations of increased ERK1/2 phosphorylation and
increased c-myc phosphorylation accompanying the increased cyclin
D2 expression were also mirrored in vivo in the Nox4 Tg mouse hearts,
suggesting an equivalent ERK1/2-dependent molecular pathway. There-
fore our data may be consistent with, and build upon, a previous report
in which cardiac-speciﬁc overexpression of insulin-like growth factor
1B (IGF-1B) resulted in increased postnatal cardiomyocyte proliferation
[55]. IGF-1B has been shown to both induce ROS production mediated
by Nox4 [56], and to activate ERK1/2 [57]. Thus it seems likely that
Nox4 may be involved in the increased cardiomyocyte cell cycling ob-
served in this mouse model. It may also be highly signiﬁcant that inap-
propriate ERK1/2 hyperphosphorylation in embryonic hearts has been
shown previously to result in congenital cardiac defects resulting from
altered cardiomyocyte cell cycling [58]. The cardiac-speciﬁc expression
of Nox4 in our Tg mouse model is driven by the αMHC promoter,
which is not activated in the embryo, but directs expression only in the
postnatal animal [29]. It may be that embryonic-stage cardiomyocytes,
which are already very proliferative, have an increased susceptibility to
and are therefore less tolerant of, increased ERK1/2 activation.
In this mouse model, Nox4 overexpression appears to prolong the
period of cardiomyocyte proliferation soon after birth, but was not suf-
ﬁcient, in the adult mouse to maintain increased cardiomyocyte cell-
cycling. In this respect, the phenotype of the Nox4 Tg mouse is similar
to that of the p27KIP1 knockout mouse. Thus ablation of the cell cycle
inhibitor, p27KIP1, allowed additional rounds of proliferation in the
cardiac myocyte population of neonatal mice but was not, in itself,sufﬁcient to prevent exit from the cell cycle [59]. Clearly, a multitude
of factors are needed to overcome cardiac cell cycle arrest and promote
full cellular proliferation in the adult heart. The enlarged heart size in
the Nox4 Tg mice was progressively lost before 7 weeks of age, despite
a sustained increase in ERK1/2 activation and cyclin D2 (mRNA and pro-
tein) expression. One might predict that this “normalisation” in the
heart size might reﬂect less hypertrophic growth in the (more numer-
ous)Nox4 Tg cardiomyocytes, and therefore the average cardiomyocyte
size would be signiﬁcantly smaller in the Nox4 Tg adult mice, compared
to age-matched Wt controls. Perhaps surprisingly, however, we found
no signiﬁcant differences in the mean cardiomyocyte volumes, either
by taking physical measurements of isolated cells or by takingmeasure-
ments on a Coulter Counter. The complex mechanisms whereby cells
and organs maintain size homeostasis are poorly understood, and
must involve the coordinated regulation of cell growth, proliferation
and survival pathways [60], andwould need to be extensively examined
to fully explain our observations here.
Not surprisingly, these Nox4 Tgmice show striking phenotypic sim-
ilarities to cardiac-speciﬁc cyclin D2 Tgmice [24,32]. In particular in one
study, cyclin D2 overexpression was speciﬁcally shown to increase pro-
liferation in thepostnatal heart, resulting in increased cardiac growth, as
we describe here [24]. However in both these studies the increased
heart weight: body weight ratio, and increased cardiomyocyte DNA
synthesis persisted into the adult. By contrast both these phenotypes
were lost in the Nox4 Tg mice by 7 weeks of age, and we demonstrate
this to correlate with the complete loss of cyclin D2 localised within
the nucleus. It is notable that in the cyclin D2 Tg mice described, a
very high level of expression of the transgene (driven by theαMHCpro-
moter)was achieved, and some nuclear expression of cyclin D2was ob-
served in the adult mouse [32]. Therefore the differences in levels of
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count for these differences. Interestingly, the cardiac-speciﬁc cyclin D2
transgenic mouse has been shown to be cardiac-protective in a numberFig. 8. Forced expression of Nox4 in the postnatal heart prolongs the period of myocyte prolife
(n= 3/4), 5 weeks (n= 6/6), 7 weeks (n= 13/9) and 12 weeks (n= 13/13) post-birth. *P b
7 week-old Wt and Tg mice additionally analysed by one-way ANOVA with Bonferroni
(B) Representative immunoﬂuorescence staining of transverse frozen heart sections from 7 w
(green), cardiac troponin T (red) and the cell nuclei stain DAPI (blue). No Ki67-positive cardiom
titativehistogram showing increased ERK1/2phosphorylation in 7week oldNox4Tgheartswhe
2 to total ERK1/2 protein levels (n = 3). (D) Q-PCR analyses of cyclin D2mRNA levels in 7 wee
immunoblot showing cyclin D2 protein expression levels in 7 week oldWt and Nox4 Tg mice, c
and Nox4 Tg adult cardiomyocytes isolated from 13 week old male mice (n = 3/3). Cell volum
subsequent calculation of volume based on these parameters (see Section 2, Materials a
I) Representative immunoblots demonstrating cytoplasmic and nuclear localisation of cyclin D
Staining for lamin A/C and α-tubulin demonstrates successful fractionation of nuclear and cyt
at 2 days, and in Tg hearts only at 11 days after birth. No nuclear cyclin D2 is apparent in Wt oof different assays. Thus it demonstrated increased cardiomyocyte
cycling after permanent coronary arterial occlusion,with a subsequence
regression in infarct size and an improvement in cardiac function [61]ration. (A) Quantiﬁcation of heart/body weight ratios of Wt and Nox4 Tg mice at 3 weeks
0.05, 2-tailed Student's t-test. Ns: not signiﬁcant. Heart/bodyweight ratios of 5 week and
post-hoc test showed signiﬁcant change at 5 weeks (P b 0.05) are lost at 7 weeks.
eek old Nox4 Tg mice co-stained with an antibody against the proliferation marker Ki67
yocytes are visible at this time point. Scale bar, 50 μm. (C) Representative blot and quan-
n comparedwithWt controls. The histogramrepresents the ratio of phosphorylated ERK1/
k old Wt and Nox4 Tg mice, relative to levels of β-actin mRNA (n= 3). (E) Representative
ompared to those of β-actin. (F) Histogram indicating cell volumes in pico litres (pl) of Wt
es were assessed by physical measurements of length and cross sectional diameter, and
nd methods). (C, D, F) *P b 0.05, 2-tailed Student's t-test. Ns: not signiﬁcant. (G, H,
2 in Wt and Nox4 Tg mouse hearts at 2 days (G), 11 days (H) and 7 weeks (I) after birth.
oplasmic proteins, respectively. Nuclear cyclin D2 is apparent in Wt and Tg mouse hearts
r Tg hearts of the adult mice.
Fig. 8 (continued).
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myocardial ﬁbrosis resulting from cardiac-speciﬁc TGFβ-overexpression
[62]. The ﬁnding that in the present study Nox4-overexpression acts to
increase cyclin D2 expression therefore warrants investigation of its ef-
fects on cardiac function and adaptation in disease models.
The elucidation of the molecular pathway modulating the ROS-
dependent increase in cardiomyocyte cycling offers the possibility of
targeting components of this pathway therapeutically. One promising
potential target is the protein tyrosine phosphatase Src homology re-
gion 2, phosphatase 2 (SHP2). SHP2 is known to be a positive mediator
of ERK1/2 signalling, and cardiac-speciﬁc increased activity of SHP2
leads to increased cardiomyocyte cell cycling and resultant defects
within the embryonic heart. However, in the postnatal heart SHP2 hy-
peractivity is completely benign [58]. Although the cycling capacity of
the cardiomyocytes was not assessed in these experiments, the ERK1/
2 activation mediated by the increased SHP2 activity was shown to be
upregulated in the postnatal mouse hearts. The transcriptional regula-
tion of cyclin D2 by c-mycmay also be amechanismaffording therapeu-
tic intervention. The binding of c-myc to the cyclin D2 promoter is
known to depend on the dimerization with a partner protein, Max,
which is inhibited by histone deacetylase (HDAC) activity, and en-
hanced by histone acetyl transferase (HAT) complexes [36,37]. Thus ap-
propriate small molecule modulators of HDAC/HAT activities [63,64]
may prove therapeutically useful in helping to promote cardiomyocyte
cycling after ischaemic injury.
The question as to the endogenous source(s) of ROSwhichmaymod-
ulate cardiomyocyte cell cycling in vivo is not fully addressed here. The
family of NADPH oxidases, and in particular Nox4 seems a likely candi-
date to effect this redox regulation in cardiomyocytes in vivo. However,
Nox4 KO mice show no obvious defect in cardiac structure or function
under “baseline” physiological conditions [16], suggesting that Nox4
may not have an obligatory role. Nevertheless, the observation that en-
dogenous Nox4 expression declines sharply after birth, together with
the potential for the Nox4-mediated, enhancement of cardiomyocyte
proliferation demonstrated here, suggest that redox signalling mediated
by Nox4 may be an important pro-proliferative mechanism that be-
comes downregulated and contributes to cardiomyocyte cycle arrest in
the postnatal mammalian heart.
4.2. Conclusions
The cardiomyocyte cell cycle is regulated by redox-dependent
signalling pathway(s) in vivo. Nox4 is demonstrated here to be an im-
portant potential source of ROS mediating such pathways, and overex-
pression of Nox4 results in increased cardiomyocyte cell cycling in theheart soon after birth. In vitrowe demonstrate a pathway leading to in-
creased cardiomyocyte proliferation, inwhichNox4-generated ROS acts
to mediate ERK1/2 activation and subsequent phosphorylation of the
transcription factor c-myc. c-Myc in turn acts to upregulate cyclin D2
expression, which is known to be both necessary and sufﬁcient to
drive cardiomyocyte proliferation in vitro. We present evidence that
this same pathway acts in vivo to increase cardiomyocyte cell cycling
upon Nox4 overexpression.
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.yjmcc.2014.10.017.
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